Who we are
Medicines for Europe
Purpose and Objectives
OUR VALUES
STRUCTURE
OUR MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
JOB OPPORTUNITIES
Key topics
COVID-19
Access
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
ENVIRONMENT
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
Publications
Factsheets
Infographics
Reports
Policy
Videos
Newsroom
Press releases
In the news
Press kit
Contact us
Login
Generic medicines
Home
Who we are
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Who we are
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Environment of value added medicines in Europe
Definition
THERAPEUTIC AREAS
Q&A
What’s new
Environment of value added medicines in Europe
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Value Added Medicines award 2019
QUOTES
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
The Issue of Abuses of Divisional Patent Application
Open
VALUE ADDED MEDICINES ONLINE SUMMIT Empowering the healthcare community by improving existing treatments
Open
Biosimilar Medicine Market Review 2020
Open
Заповнення прогалини: Filling the gap – Ukrainian translation now available.
Filling the gap – how off-patent medicines can improve the equity and quality of cancer care – Ukrainian translation now available.
Open Ukrainian translation
EU industrial policy can dramatically improve medicines manufacturing resilience and security of supply
Open
Medicines for Europe Position on IP Action Plan – March 2021
Open
Maintaining the exchange of critical health data – An adequacy decision on the UK data protection regime
Open
Medicines for Europe Position Paper On Patent Linkage
Open
Market Review – European Generic Medicine Markets 2020
Open
Medicines for Europe Position Paper on Bolar Exemption – Feb 2021
Open
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
